Dr. Harrold is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Lake Ave N
Department Of Rheumatology
Worcester, MA 01655Phone+1 508-334-5224
Education & Training
- UMass Chan Medical SchoolFellowship, Rheumatology, 1995 - 1998
- UMass Chan Medical SchoolResidency, Internal Medicine, 1992 - 1995
- University of Massachusetts Medical SchoolClass of 1992
Certifications & Licensure
- MA State Medical License 1997 - 2020
- CT State Medical License Active through 2013
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
- Fellow (FACR) American College of Rheumatology
Publications & Presentations
PubMed
- Effectiveness of tofacitinib versus tumor necrosis factor inhibitors and in those receiving tofacitinib as different lines of therapy in patients with rheumatoid arthr...Leslie R Harrold, Clifton O Bingham, Janet E Pope, Jacqueline O'Brien, Page C Moore
Clinical Rheumatology. 2024-12-20 - Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis.Joshua F Baker, George Reed, Ted R Mikuls, Geoffrey M Thiele, Dimitrios A Pappas
Arthritis & Rheumatology. 2024-10-17 - 1 citationsDisease activity of rheumatoid arthritis and kidney function decline: a large prospective registry study.Sho Fukui, Wolfgang C Winkelmayer, Sara K Tedeschi, Javier Marrugo, Hongshu Guan
Annals of the Rheumatic Diseases. 2024-08-21
Journal Articles
- Oxford University Press Has Registered This DOI Pre-PublicationLeslie Harrold, MD, Oxford University Press
Press Mentions
- Bristol Myers Squibb Data at ACR Convergence 2021 Illustrate Scientific Advances for Immune-Mediated Rheumatic DiseasesNovember 3rd, 2021
- Treatment Failing Majority of RA PatientsNovember 27th, 2019
- Bristol-Myers Squibb Underscores Precision-Focused Immunology Leadership with New Data on ORENCIA® (Abatacept) in Early RA, ACPA-Positive Patients Presented at 2019 ACR/ARP Annual Meeting1November 7th, 2019
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: